Adjunct therapy for sepsis: How early?

被引：6

作者：

Annane D. ^{[1
]}

机构：

[1] General Intensive Care Unit, Raymond Poincaré Hospital (AP-HP), University of Versailles SQY, 92380 Garches

来源：

Current Infectious Disease Reports | 2010年 / 12卷 / 5期

关键词：

Activated protein C; Apoptosis; Coagulation; Hydrocortisone; Infection; Inflammation; Organ dysfunction; Shock;

D O I：

10.1007/s11908-010-0123-2

中图分类号：

学科分类号：

摘要：

Sepsis is a leading cause of death worldwide. The management of patients is primarily based on curing the infectious process with anti-infective drugs and/or surgical drainage. Simultaneously, treatment includes optimization of oxygen use by tissues via appropriate oxygen therapy and respiratory and hemodynamic management. At best, initiating appropriate anti-infective and symptomatic treatments should lead to patient improvement within a few hours. Activated protein C and hydrocortisone are the only two available adjunct therapies for sepsis. These treatments should optimally be started within 24 hours of the onset of shock. They should be initiated in those patients who did not adequately respond after 6 hours of optimal anti-infective and symptomatic treatments. © 2010 Springer Science+Business Media, LLC.

引用

页码：361 / 367

页数：6

共 41 条

[11] Cronin L., Cook D.J., Carlet J., Et al., Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature, Crit Care Med, 23, pp. 1430-1439, (1995)
[12] Annane D., Sebille V., Troche G., Et al., A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin, JAMA, 283, pp. 1038-1045, (2000)
[13] Marik P.E., Pastores S.M., Annane D., Et al., Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine, Crit Care Med, 36, pp. 1937-1949, (2008)
[14] Annane D., Bellissant E., Bollaert P.E., Et al., Corticosteroids in the treatment of severe sepsis and septic shock in adults: A systematic review, JAMA, 301, pp. 2362-2375, (2009)
[15] Annane D., Cariou A., Maxime V., Et al., Corticosteroid treatment and intensive insulin therapy for septic shock in adults: A randomized controlled trial, JAMA, 303, pp. 341-348, (2010)
[16] Sprung C., Annane D., Keh D., Et al., The CORTICUS randomized, double-blind, placebo-controlled study of hydrocortisone therapy in patients with septic shock, N Engl J Med, 358, pp. 111-124, (2008)
[17] Dellinger R.P., Levy M.M., Carlet J.M., Et al., Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008, Crit Care Med, 36, pp. 296-327, (2008)
[18] Hinshaw L.B., Archer L.T., Beller-Todd B.K., Et al., Survival of primates in lethal septic shock following delayed treatment with steroid, Circ Shock, 8, pp. 291-300, (1981)
[19] Cicarelli D.D., Vieira J.E., Bensenor F.E., Early dexamethasone treatment for septic shock patients: A prospective randomized clinical trial, Sao Paulo Med J, 125, pp. 237-241, (2007)
[20] Yildiz O., Doganay M., Aygen B., Et al., Physiologic-dose steroid therapy in sepsis, Crit Care, 6, pp. 251-259, (2002)

← 1 2 3 4 5 →